Richard Lindstrom, MD.

PLEASANTON, Calif.—Surface Ophthalmics, a pioneering biopharmaceutical company, has announced the appointment of Richard Lindstrom, MD, as founder and chairman. A highly acclaimed physician and surgeon in ophthalmology, Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, P.A. Dr. Lindstrom will lead in partnership with the company’s board of directors, including Adrienne Graves, PhD, lead director; Perry J. Sternberg, Shelley Thunen, and J. Andy Corley. In the U.S. alone, an estimated 38 million people have some form of dry eye syndrome (DES); however, only 17 million are diagnosed and only 1.7 million are using a prescription therapy.

With its product portfolio in development, Surface Ophthalmics seeks to address the full range of DES, from episodic to chronic, by providing eyecare professionals targeted therapies to treat the signs, symptoms and underlying causes of DES, which can be naturally occurring or following ocular surgery.

“I am honored and thrilled to lead Surface Ophthalmics into its next phase of expansion as we work to advance the company’s innovative and proprietary medicinal candidates for patients suffering from DES,” said Dr. Lindstrom. “Our solutions hold significant potential to meet existing gaps in care, and I’m eager to collaborate with our talented team to introduce these products to the market.”

 
 
Surface Ophthalmics is advancing Kera So Tears, an over-the-counter artificial tear solution designed for cell-compatible, short-term, fast-acting, temporary relief of burning and irritation caused by dryness of the eye, and is progressing the clinical program for its investigational drug, Mycosol (Surf-101), a first-in-class prescription eye drop that delivers Mycophenolate in Surface’s proprietary formulation. This combination is designed to provide sustained immunosuppressive action and mucin upregulation at the ocular surface. To learn more click here.